Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases

Atsuo Kanno; Natsuko Tanimura; Masayuki Ishizaki; Kentaro Ohko; Yuji Motoi; Masahiro Onji; Ryutaro Fukui; Takaichi Shimozato; Kazuhide Yamamoto; Takuma Shibata; Shigetoshi Sano; Akiko Sugahara-Tobinai; Toshiyuki Takai; Umeharu Ohto; Toshiyuki Shimizu; Shin Ichiroh Saitoh; Kensuke Miyake

doi:10.1038/ncomms7119

Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases

Atsuo Kanno, Natsuko Tanimura, Masayuki Ishizaki, Kentaro Ohko, Yuji Motoi, Masahiro Onji, Ryutaro Fukui, Takaichi Shimozato, Kazuhide Yamamoto, Takuma Shibata, Shigetoshi Sano, Akiko Sugahara-Tobinai, Toshiyuki Takai, Umeharu Ohto, Toshiyuki Shimizu, Shin Ichiroh Saitoh, Kensuke Miyake

Division of Aging Science

Research output: Contribution to journal › Article › peer-review

44 Citations (Scopus)

Abstract

Toll-like receptor 7 (TLR7) senses microbial-derived RNA but can also potentially respond to self-derived RNA. To prevent autoimmune responses, TLR7 is thought to localize in endolysosomes. Contrary to this view, we show here that TLR7 is present on the cell surface of immune cells and that TLR7 responses can be inhibited by an anti-TLR7 antibody. The anti-TLR7 antibody is internalized with TLR7 and accumulates in endolysosomes as an immune complex. TLR7 responses in dendritic cells, macrophages and B cells are all inhibited by the anti-TLR7 antibody. Furthermore, the anti-TLR7 antibody inhibits in vivo cytokine production induced by a TLR7 ligand. Spontaneous TLR7 activation in Unc93b1 D34A/D34A mice causes lethal inflammation. Progressive inflammation such as splenomegaly, thrombocytopenia and chronic active hepatitis are ameliorated by anti-TLR7 antibody treatment. These results demonstrate that cell surface TLR7 is a promising target for therapeutic intervention in autoimmune diseases.

Original language	English
Article number	6119
Journal	Nature communications
Volume	6
DOIs	https://doi.org/10.1038/ncomms7119
Publication status	Published - 2015 Feb 4

ASJC Scopus subject areas

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
Physics and Astronomy(all)

Access to Document

10.1038/ncomms7119

Fingerprint Dive into the research topics of 'Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases'. Together they form a unique fingerprint.

Cite this

Kanno, A., Tanimura, N., Ishizaki, M., Ohko, K., Motoi, Y., Onji, M., Fukui, R., Shimozato, T., Yamamoto, K., Shibata, T., Sano, S., Sugahara-Tobinai, A., Takai, T., Ohto, U., Shimizu, T., Saitoh, S. I., & Miyake, K. (2015). Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases. Nature communications, 6, [6119]. https://doi.org/10.1038/ncomms7119

Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases. / Kanno, Atsuo; Tanimura, Natsuko; Ishizaki, Masayuki; Ohko, Kentaro; Motoi, Yuji; Onji, Masahiro; Fukui, Ryutaro; Shimozato, Takaichi; Yamamoto, Kazuhide; Shibata, Takuma; Sano, Shigetoshi; Sugahara-Tobinai, Akiko; Takai, Toshiyuki; Ohto, Umeharu; Shimizu, Toshiyuki; Saitoh, Shin Ichiroh; Miyake, Kensuke.

In: Nature communications, Vol. 6, 6119, 04.02.2015.

Research output: Contribution to journal › Article › peer-review

Kanno, Atsuo ; Tanimura, Natsuko ; Ishizaki, Masayuki ; Ohko, Kentaro ; Motoi, Yuji ; Onji, Masahiro ; Fukui, Ryutaro ; Shimozato, Takaichi ; Yamamoto, Kazuhide ; Shibata, Takuma ; Sano, Shigetoshi ; Sugahara-Tobinai, Akiko ; Takai, Toshiyuki ; Ohto, Umeharu ; Shimizu, Toshiyuki ; Saitoh, Shin Ichiroh ; Miyake, Kensuke. / Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases. In: Nature communications. 2015 ; Vol. 6.

@article{c1acf35e08344bd1a95c7ec04fae7996,

title = "Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases",

abstract = "Toll-like receptor 7 (TLR7) senses microbial-derived RNA but can also potentially respond to self-derived RNA. To prevent autoimmune responses, TLR7 is thought to localize in endolysosomes. Contrary to this view, we show here that TLR7 is present on the cell surface of immune cells and that TLR7 responses can be inhibited by an anti-TLR7 antibody. The anti-TLR7 antibody is internalized with TLR7 and accumulates in endolysosomes as an immune complex. TLR7 responses in dendritic cells, macrophages and B cells are all inhibited by the anti-TLR7 antibody. Furthermore, the anti-TLR7 antibody inhibits in vivo cytokine production induced by a TLR7 ligand. Spontaneous TLR7 activation in Unc93b1 D34A/D34A mice causes lethal inflammation. Progressive inflammation such as splenomegaly, thrombocytopenia and chronic active hepatitis are ameliorated by anti-TLR7 antibody treatment. These results demonstrate that cell surface TLR7 is a promising target for therapeutic intervention in autoimmune diseases.",

author = "Atsuo Kanno and Natsuko Tanimura and Masayuki Ishizaki and Kentaro Ohko and Yuji Motoi and Masahiro Onji and Ryutaro Fukui and Takaichi Shimozato and Kazuhide Yamamoto and Takuma Shibata and Shigetoshi Sano and Akiko Sugahara-Tobinai and Toshiyuki Takai and Umeharu Ohto and Toshiyuki Shimizu and Saitoh, {Shin Ichiroh} and Kensuke Miyake",

year = "2015",

month = feb,

day = "4",

doi = "10.1038/ncomms7119",

language = "English",

volume = "6",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases

AU - Kanno, Atsuo

AU - Tanimura, Natsuko

AU - Ishizaki, Masayuki

AU - Ohko, Kentaro

AU - Motoi, Yuji

AU - Onji, Masahiro

AU - Fukui, Ryutaro

AU - Shimozato, Takaichi

AU - Yamamoto, Kazuhide

AU - Shibata, Takuma

AU - Sano, Shigetoshi

AU - Sugahara-Tobinai, Akiko

AU - Takai, Toshiyuki

AU - Ohto, Umeharu

AU - Shimizu, Toshiyuki

AU - Saitoh, Shin Ichiroh

AU - Miyake, Kensuke

PY - 2015/2/4

Y1 - 2015/2/4

N2 - Toll-like receptor 7 (TLR7) senses microbial-derived RNA but can also potentially respond to self-derived RNA. To prevent autoimmune responses, TLR7 is thought to localize in endolysosomes. Contrary to this view, we show here that TLR7 is present on the cell surface of immune cells and that TLR7 responses can be inhibited by an anti-TLR7 antibody. The anti-TLR7 antibody is internalized with TLR7 and accumulates in endolysosomes as an immune complex. TLR7 responses in dendritic cells, macrophages and B cells are all inhibited by the anti-TLR7 antibody. Furthermore, the anti-TLR7 antibody inhibits in vivo cytokine production induced by a TLR7 ligand. Spontaneous TLR7 activation in Unc93b1 D34A/D34A mice causes lethal inflammation. Progressive inflammation such as splenomegaly, thrombocytopenia and chronic active hepatitis are ameliorated by anti-TLR7 antibody treatment. These results demonstrate that cell surface TLR7 is a promising target for therapeutic intervention in autoimmune diseases.

AB - Toll-like receptor 7 (TLR7) senses microbial-derived RNA but can also potentially respond to self-derived RNA. To prevent autoimmune responses, TLR7 is thought to localize in endolysosomes. Contrary to this view, we show here that TLR7 is present on the cell surface of immune cells and that TLR7 responses can be inhibited by an anti-TLR7 antibody. The anti-TLR7 antibody is internalized with TLR7 and accumulates in endolysosomes as an immune complex. TLR7 responses in dendritic cells, macrophages and B cells are all inhibited by the anti-TLR7 antibody. Furthermore, the anti-TLR7 antibody inhibits in vivo cytokine production induced by a TLR7 ligand. Spontaneous TLR7 activation in Unc93b1 D34A/D34A mice causes lethal inflammation. Progressive inflammation such as splenomegaly, thrombocytopenia and chronic active hepatitis are ameliorated by anti-TLR7 antibody treatment. These results demonstrate that cell surface TLR7 is a promising target for therapeutic intervention in autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=84929640671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929640671&partnerID=8YFLogxK

U2 - 10.1038/ncomms7119

DO - 10.1038/ncomms7119

M3 - Article

AN - SCOPUS:84929640671

VL - 6

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 6119

ER -